NCT01492166View on ClinicalTrials.gov

Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical Practice

CompletedOBSERVATIONAL
Enrollment

1,935

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

biphasic human insulin 30

Dose and timing of dose for each subject was at the discretion of the attending physicians based on current clinical practice guidelines

Trial Locations (1)

12520

Novo Nordisk Investigational Site, Jakarta

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY